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Background
HIV viral diversity and baseline (BL) substitutions have
implications for response to antiretroviral therapy, the
development of resistance and disease progression.
Worldwide, approximately 90% of HIV infections are
non-B subtypes. The CASTLE study is a randomized,
open-label, prospective study comparing once-daily ATV/
r with twice-daily LPV/r, both in combination with fixed-
dose tenofovir/emtricitabine in 883 treatment-naive
patients from 28 countries. The impact of HIV subtypes
and BL resistance on efficacy and emergence of resistance
is described.
Methods
HIV subtype was determined by comparison of genotypes
with a consensus B sequence. Protease substitutions were
classified as major or minor according to IAS-USA (2007)
and the HIV Drug Resistance Database (HIVdb). Protease
polymorphisms were defined as either: 1) IAS-USA minor
substitutions assigned a score of 0 by the Stanford HIV
database (HIVdb Genotype Resistance Interpretation); or
2) Non-IAS-USA PI substitutions (Clade B reference).
Batched genotypes were performed on BL samples, and
Genotype/PhenoSense (Monogram Biosciences, South
San Francisco, CA, USA) on paired samples with virologic
failure (HIV-RNA = 400 c/mL) through week 48 (i.e.
rebound without resuppression; never confirmed VL<400
c/mL but remained on treatment at week 48; discontinued
due to lack of efficacy before week 48).
Summary of results
18 HIV subtypes were represented: B (66%), C (16%), BF
(8%), and AE (6%). Response rates overall and by subtype
are presented in Table 1.
Response rates by baseline substitutions are presented in
Table 2.
6% of subjects in each treatment group had virologic fail-
ure. PI substitutions emerged in 10/19 ATV/r and 8/20
LPV/r VFs; all were polymorphic except in two ATV/r sub-
jects [1(N88S, M46I); 2 (L10F, V32I, M46I, K43T, A71I,
G73S, L90M)]. The subject with N88S subsequently re-
suppressed to undetectable levels on same regimen (ATV
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Table 1: Confirmed Virologic Response (CVR) VL<50 at Wk 48 
(ITT).
ATV/r n/N (%) LPV/r n/N (%)
Overall* 343/440 (78) 338/443 (76)
Subtype B 230/291 (79) 210/283 (74)
Subtype Non-B 107/143 (75) 121/148 (82)
AE 23/28 (82) 25/28 (89)
BF 21/27 (78) 31/38 (82)
C 51/73 (70) 52/65 (80)
Other 12/15 (80) 13/17 (76)
* Estimated difference: 1.7 (95% CI, -3.8%, 7.1%). 18 reported HIV 
subtypes contain 6 subtypes, 3 sub-subtypes and 9 recombinants.Page 1 of 2
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FC 3.71); M184V emerged in 5/19 and 4/20, and TAMs in
1/19 and 1/20, respectively. Virologic failure rates were
consistent across the predominant subtypes represented
in the study: ATV/r (B 5%, C 8%) and LPV/r (B 6%, C 8%).
Conclusion
Both regimens (ATV/r and LPV/r) achieved consistently
high response rates regardless of HIV subtype or BL substi-
tutions. Both regimens had infrequent emergence of non-
polymorphic PI substitutions with virologic failure, and
similar rates of selection of antiretroviral resistance muta-
tions.
Table 2: Confirmed Virologic Response (CVR) VL<50 at Wk 48 
(ITT) by Baseline Substitutions.
ATV/r n/N (%) LPV/r n/N (%)
PI-IAS-USA Major/Minor 0 224/290 (77) 202/257 (79)
PI-IAS-USA Major/Minor 1–2 110/138 (80) 128/170 (75)
PI-IAS-USA Major/Minor ≥ 3 3/3 (100) 1/2 (50)
PI Polymorphisms ≥ 5 191/251 (76) 173/222 (78)
NRTI (any IAS or Stanford) ≥ 1 57/73 (78) 51/64 (80)
* Estimated difference: 1.7 (95% CI, -3.8%, 7.1%). 18 reported HIV 
subtypes contain 6 subtypes, 3 sub-subtypes and 9 recombinants.Page 2 of 2
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